Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft

被引:37
|
作者
Grinyo, JM
Gil-Vernet, S
Seron, D
Hueso, M
Fulladosa, X
Cruzado, JM
Moreso, F
Fernandez, A
Torras, J
Riera, L
Castelao, AM
Alsina, J
机构
[1] Univ Barcelona, CSUB, Bellvitge Hosp, Dept Nephrol,Serv Nefrol, Barcelona 08907, Spain
[2] Univ Barcelona, CSUB, Bellvitge Hosp, Dept Urol, Barcelona 08907, Spain
关键词
antithymocyte globulin; mycophenolate mofetil; suboptimal grafts;
D O I
10.1093/ndt/13.10.2601
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background, In renal transplantation the beneficial immunosuppressive effects of cyclosporin (CsA) may be curtailed by its nephrotoxicity, specially in patients receiving a cadaveric allograft from suboptimal donors or at risk of delayed graft function. Mycophenolate mofetil (MMF) and antithymocyte globulin (ATG) have each demonstrated to be potent immunosuppressants in renal transplantation. In a prospective analysis we have studied the results at 6 months of the combination of MMF, ATG and low-dose steroids in patients with low immunological risk receiving a first cadaveric renal allograft from a suboptimal donor or at risk of delayed graft function. Methods. Patients with preformed reactive antibodies < 50% receiving a first graft from a suboptimal donor (age greater than or equal to 40 years, non-heart-beating, acute renal failure, arterial hypertension) or at risk of delayed graft function (cold ischaemia time greater than or equal to 24 h) were eligible for this open single-arm pilot trial. From September 1996 to March 1997 we recruited 17 patients. They were treated with MMF 2 g p.o, preoperatively, and after transplantation at 3 g/day; rabbit ATG i.v. at 2 mg/kg preoperatively, and 1.5 mg/kg/day the first day after transplantation, followed by four doses of 1 mg/kg on alternate days; prednisone was given at 0.25 mg/kg/day and reduced progressively to 0.1 mg/kg/day at 3 months. Primary outcomes were incidence of biopsy-proven acute rejection, delayed graft function, opportunistic infections, graft and patient survival, and the need for introduction of CsA treatment. Results. delayed graft function occurred in two cases (12%). Four of 17 patients (24%) had a biopsy-proven acute rejection (2 grade I and 2 grade II) within the first 3 months after transplantation. CsA was added in two cases with grade II biopsy-proven acute rejection, and in one with grade I biopsy-proven acute rejection. In one patient MMF was replaced by CsA because of gastrointestinal intolerance. Mean serum creatinine 6 months after transplantation was 159+/-59 mu mol/l. Cytomegalovirus tissue invasive disease occurred in one patient (6%). At 6 months followup all patients are alive with functioning allografts. Conclusions. These preliminary results suggest that in low-immunological-risk patients who receive a suboptimal renal allograft or at risk of delayed graft function, the combination of MMF, ATG, and steroids is an efficient immunosuppressive regime that may avoid the use of CsA in 70% of the recipients.
引用
收藏
页码:2601 / 2604
页数:4
相关论文
共 50 条
  • [1] Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients
    Ciancio, G
    Burke, GW
    Suzart, K
    Roth, D
    Kupin, W
    Rosen, A
    Olson, L
    Esquenazi, V
    Miller, J
    TRANSPLANTATION, 2002, 73 (07) : 1100 - 1106
  • [2] Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression
    Ciancio, G
    Miller, A
    Burke, GW
    Gharagozloo, H
    Rosen, A
    Roth, D
    Kupin, W
    Pinna, A
    Cespedes, M
    Esquenazi, V
    Miller, J
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1013 - 1014
  • [3] Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil and steroids as maintenance immunosuppression.
    Roth, D
    Kuehnel, F
    Angelis, M
    Colona, J
    Burke, G
    Ciancio, G
    Esquenazi, V
    Miller, J
    TRANSPLANTATION, 1999, 67 (09) : S602 - S602
  • [4] Mycophenolate Dose Reductions Contribute to Suboptimal Graft Outcomes in Kidney Transplant Recipients
    Boyle, K.
    Fleming, J.
    Taber, D.
    Covert, K.
    Casale, J.
    Staino, C.
    Pilch, N.
    Mardis, C.
    Meadows, H.
    Srinivas, T.
    McGillicuddy, J.
    Chavin, K.
    Bratton, C.
    Baliga, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [5] Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients
    Yeung, S
    Tsang, WK
    Tong, KL
    Wong, SH
    Lee, W
    Tang, HL
    Chan, HWH
    Chan, AYW
    TRANSPLANTATION PROCEEDINGS, 2004, 36 (07) : 2084 - 2086
  • [6] Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients
    Teebken, OE
    Strüber, M
    Harringer, W
    Pichlmaier, MA
    Haverich, A
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (04) : 1265 - 1268
  • [7] Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients
    Renz, JF
    Lightdale, J
    Mudge, C
    Bacchetti, P
    Watson, J
    Ascher, NL
    Emond, JC
    Rosenthal, P
    Roberts, JP
    LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (02): : 136 - 143
  • [8] Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients.
    Brueckner, A.
    Yanqui, E.
    Truong, C.
    Baliga, R.
    Bowman, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 823 - 823
  • [9] Efficacy and safety of Daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression
    Ciancio, G
    Burke, GW
    Suzart, K
    Vaidya, A
    Roth, D
    Kupin, W
    Mattiazzi, A
    Rosen, A
    Esquenazi, V
    Miller, J
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (02) : 873 - 874
  • [10] Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipients with sirolimus-based immunosuppression
    El-Agroudy, Amgad E.
    El-Dahshan, Khaled F.
    Wafa, Ehab W.
    Sheashaa, Hussien A.
    Gad, Ziad A.
    Ismail, Amani M.
    Shokeir, Ahmed A.
    Ghoneim, Mohamed A.
    NEPHROLOGY, 2009, 14 (02) : 255 - 261